Novo Nordisk is contesting Sen. Bernie Sanders’ calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Novo Nordisk defends $1,000 Ozempic list price
